![]() Results were published in New England Journal of Medicine here. The efficacy of Andexanet alfa was examined in ANNEXA-A and ANNEXA-R. In US, andexanet alfa is a recombinant coagulation factor Xa (inactivated-zhzo) which is indicated for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life threatening or uncontrolled bleeding. So I think it is time to take a closer look at this new antidote and its role in reversing the effects of anti-factor Xa agents. It’s only a matter of time that this reversal agent will become available in Canada. This agent can reverse the effects of rivaroxaban and apixaban. FDA has recently approved the new antidote for reversal of factor Xa inhibitors – Andexxa® (andexanet alfa).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |